ClinicalTrials.Veeva

Menu
T

The Center for Clinical Trials | Saraland, AL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Empagliflozin
Linaclotide
SPN-812
Ferric Maltol
sodium
Eluxadoline
Loperamide
Iron
Ferrous Sulfate
Inclisiran

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 10 total trials

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Active, not recruiting
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Enrolling
Attention-Deficit/Hyperactivity Disorder
Drug: Placebo
Drug: 100mg SPN-812

LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation...

Active, not recruiting
Functional Constipation
Irritable Bowel Syndrome With Constipation
Drug: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)

Trial sponsors

AbbVie logo
Boehringer Ingelheim logo
Allergan logo
N
Novartis logo
Pfizer logo
S
Supernus Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems